We evaluated the efficacy of @entity19160 for treating @entity3457 and to compare it with @entity6383 . Group A consisted of 24 @entity1 treated for 24 months with @entity19160 300 mg i.v. for 7 days, followed by @entity19160 i.m. 100 mg for 14 days every 3 months. Group B comprised 14 @entity1 treated with @entity6383 400 mg daily for 30 days, followed by 200 mg daily for the next 11 months. In group A, 21/24 @entity1 completed the trial and obtained significant @entity158 reduction (p < 0.001), Dreiser's score (p = 0.012), and number of @entity2720 (p = 0.011). Strength of right (p = 0.04) and left (p = 0.016) hands, physician's global assessment (p  <= 0.001), and @entity1 's global assessment (p = 0.021) improved. In group B, 8/14 @entity1 completed 12 months of the study, which showed the inefficacy of @entity6383 and its lack of acceptance by @entity1 ( @entity158 and @entity1 's global assessment). Therefore, enrolment was stopped. Differences between groups showed a @entity158 decreasing trend for group A and a slightly increasing one for group B (p = 0.018). Physician and @entity1 global assessments showed a strong increase in group A compared with group B (p < 0.001). @entity19160 is effective in @entity571 ; @entity6383 seems to be ineffective.

XXXX and @entity6383 in @entity571 : a 24-month open randomized pilot study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity571 :: ('MESH:D010003', 'Disease') :: ['erosive osteoarthritis'] @entity6383 :: ('MESH:D006886', 'Chemical') :: ['hydroxychloroquine'] @entity158 :: ('MESH:D010146', 'Disease') :: ['worsening pain', 'pain'] @entity2720 :: ('MESH:D007592', 'Disease') :: ['tender joints'] @entity19160 :: ('MESH:D004002', 'Chemical') :: ['clodronate', 'Clodronate'] @entity3457 :: ('OMIM:612348', 'Disease') :: ['active erosive osteoarthritis of the hand']
@entity19160 :: (MESH:D004002,Chemical) :: ['Clodronate']
